Drd3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property |
Value |
| Gene Symbol |
DRD3 |
| Full Name |
Dopamine Receptor D3 |
| Chromosomal Location |
3q13.31 |
| NCBI Gene ID |
1818 |
| Ensembl ID |
ENSG00000151577 |
| UniProt ID |
P35462 |
| OMIM ID |
139251 |
| Protein Class |
G Protein-Coupled Receptor (Class A) |
| Species |
Human |
| Associated Diseases |
Parkinson's Disease, Restless Leg Syndrome, Schizophrenia, Dyskinesias, Addiction |
The DRD3 gene encodes the dopamine D3 receptor (D3R), a Gi/o protein-coupled receptor that is predominantly expressed in the limbic system and plays critical roles in reward, motivation, and movement control. D3R is a major therapeutic target for Parkinson's disease, particularly in the context of levodopa-induced dyskinesias, and is implicated in addiction, schizophrenia, and restless leg syndrome. The D3 receptor exhibits approximately 10-fold higher affinity for dopamine compared to the D2 receptor, making it particularly sensitive to endogenous dopamine fluctuations.
The D3 receptor is a member of the D2-like dopamine receptor family (along with DRD2 and DRD4) and couples primarily to Gi/o proteins, leading to:
- Inhibition of adenylyl cyclase: Reduces cAMP production, counteracting D1-like receptor effects
- Activation of G protein-gated potassium channels (GIRK): Causes hyperpolarization, reducing neuronal firing
- Inhibition of voltage-gated calcium channels: Reduces neurotransmitter release
- Modulation of MAPK/ERK signaling: Affects gene expression and neuronal plasticity
- β-arrestin recruitment: Triggers downstream signaling cascades
Key characteristics:
- Highest dopamine affinity among dopamine receptors (Kd ~ 0.9 nM)
- Preferential localization to limbic system regions
- Exists in both pre- and postsynaptic locations as autoreceptors and postsynaptic receptors
- Alternative splicing produces multiple receptor isoforms
- Highest expression: Nucleus accumbens (shell > core), islands of Calleja, olfactory tubercle
- High expression: Striatum (patch compartment), ventral pallidum
- Moderate expression: Substantia nigra (pars compacta), ventral tegmental area, hippocampus, amygdala
- Low expression: Cerebral cortex, cerebellum
- Kidney: High expression in renal tubules
- Immune cells: Lymphocytes, monocytes express DRD3
- Cardiovascular: Low expression in heart and blood vessels
- Endocrine: Pituitary gland expression
D3R plays a complex and central role in PD pathophysiology and treatment:
- Altered expression: Postmortem studies show increased D3R binding in the striatum of PD patients, particularly in early disease stages
- Levodopa-induced dyskinesias (LID): D3R is heavily implicated in the development of LID; D3R-deficient mice show reduced dyskinesias
- Therapeutic targeting: D3R-selective agonists (e.g., pramipexole, ropinirole) are first-line PD treatments that may have disease-modifying potential
- Genetic variants: DRD3 polymorphisms (Ser9Gly) affect PD risk, age of onset, and treatment response
- D3R vs D2R selectivity: Agonists with higher D3:D2 selectivity may reduce dyskinesia risk
- First-line treatments: D3R agonists (pramipexole, ropinirole, rotigotine) are FDA-approved for RLS
- Pathophysiology: D3R dysfunction in the mesolimbic pathway contributes to RLS sensory-motor symptoms
- Augmentation risk: Long-term use may lead to augmentation (worsening symptoms)
- Negative symptoms: D3R antagonists may improve negative symptoms and cognitive deficits
- Antipsychotic binding: Most antipsychotics have high D3R occupancy (e.g., clozapine, cariprazine)
- Gene associations: DRD3 polymorphisms linked to schizophrenia susceptibility
- Reward pathway: D3R in nucleus accumbens mediates reward conditioning
- Drug seeking: D3R antagonists reduce cocaine, alcohol, and nicotine seeking in preclinical models
- Individual vulnerability: DRD3 variants influence addiction risk
| Drug |
Type |
indications |
Notes |
| Pramipexole |
Agonist |
PD, RLS |
High D3 selectivity |
| Ropinirole |
Agonist |
PD, RLS |
D2>D3 selectivity |
| Rotigotine |
Agonist |
PD, RLS |
Transdermal patch |
| Cariprazine |
Partial agonist |
Schizophrenia, bipolar |
D3>D2 selectivity |
- D3R-selective agonists: Develop compounds with higher D3:D2 ratio to reduce dyskinesias
- Allosteric modulators: Target allosteric sites for more selective modulation
- β-arrestin biased agonists: Bias toward β-arrestin pathways may provide benefits
- Gene therapy: Viral vector delivery of D3R genes under investigation
- Enhanced baseline locomotor activity
- Reduced cocaine self-administration and reinforcement
- Altered reward processing and emotional behavior
- Improved working memory performance
- Reduced levodopa-induced dyskinesias
- D3R overexpression leads to enhanced rewarding effects of cocaine
- Humanized DRD3 mice for drug testing
- PD models with D3R manipulation show altered dyskinesia phenotypes
- Biomarkers: D3R imaging ligands for PD progression
- Personalized medicine: DRD3 genotyping for treatment selection
- Disease modification: D3R agonists as disease-modifying agents
- Combination therapies: D3R-targeted approaches with other mechanisms
The study of Drd3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:2154083 - Human dopamine D3 receptor gene: structure and expression
- PMID:8288280 - D3 receptor in the limbic system: localization and function
- PMID:10619475 - Dopamine D3 receptor and Parkinson's disease
- PMID:14598257 - Role of D3 receptors in levodopa-induced dyskinesias
- PMID:15723239 - Therapeutic targeting of dopamine D3 receptor
- PMID:19126755 - D3 receptor mechanisms in addiction
- PMID:23651826 - Restless leg syndrome and dopamine receptors
- PMID:26786091 - DRD3 polymorphisms in Parkinson's disease